Cargando…
An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
PURPOSE: The purpose of this study was to evaluate the combined measurement of serum CEA, TPA, and CA 15-3, using an individual reference limit (IRL), for predicting distant metastases in asymptomatic women following a diagnosis of primary breast cancer. METHODS: A total of 231 patients were followe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300365/ https://www.ncbi.nlm.nih.gov/pubmed/30588093 http://dx.doi.org/10.2147/CMAR.S177522 |
_version_ | 1783381665580580864 |
---|---|
author | Nicolini, Andrea Carpi, Angelo Ferrari, Paola Morganti, Riccardo Mazzotti, Valentina Barak, Vivian Duffy, Michael J |
author_facet | Nicolini, Andrea Carpi, Angelo Ferrari, Paola Morganti, Riccardo Mazzotti, Valentina Barak, Vivian Duffy, Michael J |
author_sort | Nicolini, Andrea |
collection | PubMed |
description | PURPOSE: The purpose of this study was to evaluate the combined measurement of serum CEA, TPA, and CA 15-3, using an individual reference limit (IRL), for predicting distant metastases in asymptomatic women following a diagnosis of primary breast cancer. METHODS: A total of 231 patients were followed up for a mean of 5.5±1.6 years. An IRL for defining critical changes (CCs) in marker levels was used as a warning signal of pending distant metastases. RESULTS: Sensitivity, specificity, and accuracy of the combined CEA–TPA–CA 15-3 marker panel for predicting patient outcome were 95.2%, 97.8%, and 97.9%, respectively. In all, 19 (8.3%) patients relapsed with a mean lead time to radiological evidence of metastases of 11.7±13.8 months. CONCLUSION: We concluded that the combined measurement of CA 15-3, CEA, and TPA using an IRL for determining the CC in markers levels is an accurate strategy for predicting outcome during postoperative monitoring of asymptomatic breast cancer patients. Whether the early prediction of metastasis and subsequent administration of therapy impacts on patient outcome should now be the objective of a prospective clinical trial. The marker panel described here could serve as the basis for such a trial. |
format | Online Article Text |
id | pubmed-6300365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63003652018-12-26 An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer Nicolini, Andrea Carpi, Angelo Ferrari, Paola Morganti, Riccardo Mazzotti, Valentina Barak, Vivian Duffy, Michael J Cancer Manag Res Original Research PURPOSE: The purpose of this study was to evaluate the combined measurement of serum CEA, TPA, and CA 15-3, using an individual reference limit (IRL), for predicting distant metastases in asymptomatic women following a diagnosis of primary breast cancer. METHODS: A total of 231 patients were followed up for a mean of 5.5±1.6 years. An IRL for defining critical changes (CCs) in marker levels was used as a warning signal of pending distant metastases. RESULTS: Sensitivity, specificity, and accuracy of the combined CEA–TPA–CA 15-3 marker panel for predicting patient outcome were 95.2%, 97.8%, and 97.9%, respectively. In all, 19 (8.3%) patients relapsed with a mean lead time to radiological evidence of metastases of 11.7±13.8 months. CONCLUSION: We concluded that the combined measurement of CA 15-3, CEA, and TPA using an IRL for determining the CC in markers levels is an accurate strategy for predicting outcome during postoperative monitoring of asymptomatic breast cancer patients. Whether the early prediction of metastasis and subsequent administration of therapy impacts on patient outcome should now be the objective of a prospective clinical trial. The marker panel described here could serve as the basis for such a trial. Dove Medical Press 2018-12-13 /pmc/articles/PMC6300365/ /pubmed/30588093 http://dx.doi.org/10.2147/CMAR.S177522 Text en © 2018 Nicolini et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Nicolini, Andrea Carpi, Angelo Ferrari, Paola Morganti, Riccardo Mazzotti, Valentina Barak, Vivian Duffy, Michael J An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer |
title | An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer |
title_full | An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer |
title_fullStr | An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer |
title_full_unstemmed | An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer |
title_short | An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer |
title_sort | individual reference limit of the serum cea–tpa–ca 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300365/ https://www.ncbi.nlm.nih.gov/pubmed/30588093 http://dx.doi.org/10.2147/CMAR.S177522 |
work_keys_str_mv | AT nicoliniandrea anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT carpiangelo anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT ferraripaola anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT morgantiriccardo anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT mazzottivalentina anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT barakvivian anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT duffymichaelj anindividualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT nicoliniandrea individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT carpiangelo individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT ferraripaola individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT morgantiriccardo individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT mazzottivalentina individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT barakvivian individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer AT duffymichaelj individualreferencelimitoftheserumceatpaca153tumormarkerpanelinthesurveillanceofasymptomaticwomenfollowingsurgeryforprimarybreastcancer |